Some studies support that low CD166 expression is associated with disease progression and poor clinical outcomes [53,68], while other studies state that high CD166 immunoexpression represents a marker of poor CRC prognosis [27,29]. This evidence concerns the gene ALCAM and colorectal carcinoma.